Detalhe da pesquisa
1.
[Histone deacetylase inhibitors: new synergistic third-line option in multiple myeloma]. / Histon-Deacetylase-Hemmer. Neue synergistische Drittlinienoption beim multiplen Myelom.
Med Monatsschr Pharm
; 39(4): 142-7, 2016 Apr.
Artigo
Alemão
| MEDLINE | ID: mdl-27209894
2.
Risk of Cutaneous Squamous Cell Carcinoma Development in Renal Transplant Recipients Is Independent of TMC/EVER Alterations.
Dermatology
; 231(3): 245-52, 2015.
Artigo
Inglês
| MEDLINE | ID: mdl-26227733